1. Home
  2. SUPX vs IMNM Comparison

SUPX vs IMNM Comparison

Compare SUPX & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SUPX

Super X AI Technology Limited Ordinary Shares

SELL

Current Price

$15.51

Market Cap

1.7B

Sector

N/A

ML Signal

SELL

Logo Immunome Inc.

IMNM

Immunome Inc.

HOLD

Current Price

$20.62

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SUPX
IMNM
Founded
2021
2006
Country
Singapore
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.8B
IPO Year
2024
2020

Fundamental Metrics

Financial Performance
Metric
SUPX
IMNM
Price
$15.51
$20.62
Analyst Decision
Strong Buy
Analyst Count
0
9
Target Price
N/A
$31.44
AVG Volume (30 Days)
404.4K
3.0M
Earning Date
10-24-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$3,596,575.00
$9,679,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$11.53
P/E Ratio
N/A
N/A
Revenue Growth
23.88
N/A
52 Week Low
$2.75
$5.15
52 Week High
$76.50
$25.30

Technical Indicators

Market Signals
Indicator
SUPX
IMNM
Relative Strength Index (RSI) 35.35 52.50
Support Level $14.45 $21.00
Resistance Level $19.38 $22.57
Average True Range (ATR) 2.06 1.40
MACD 1.10 -0.18
Stochastic Oscillator 24.43 29.74

Price Performance

Historical Comparison
SUPX
IMNM

About SUPX Super X AI Technology Limited Ordinary Shares

Super X AI Technology Ltd is an AI infrastructure solutions provider. Through its subsidiaries, SuperX offers a comprehensive portfolio of proprietary hardware, advanced software, and end-to-end services for AI data centers. The Company's services include advanced solution design and planning, cost-effective infrastructure product integration, and end-to-end operations and maintenance. Its core products include high-performance AI servers, High-Voltage Direct Current (HVDC) solutions, high-density liquid cooling solutions, as well as AI cloud and AI agents. The Company serves institutional clients globally, including enterprises, research institutions, and cloud and edge computing deployments.

About IMNM Immunome Inc.

Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.

Share on Social Networks: